IL213648A0 - OPTIMIZED Fc VARIANTS AND USES THEREOF - Google Patents

OPTIMIZED Fc VARIANTS AND USES THEREOF

Info

Publication number
IL213648A0
IL213648A0 IL213648A IL21364811A IL213648A0 IL 213648 A0 IL213648 A0 IL 213648A0 IL 213648 A IL213648 A IL 213648A IL 21364811 A IL21364811 A IL 21364811A IL 213648 A0 IL213648 A0 IL 213648A0
Authority
IL
Israel
Prior art keywords
variants
optimized
Prior art date
Application number
IL213648A
Other versions
IL213648A (en
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38312218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL213648(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/672,280 external-priority patent/US20040132101A1/en
Application filed by Xencor Inc filed Critical Xencor Inc
Publication of IL213648A0 publication Critical patent/IL213648A0/en
Publication of IL213648A publication Critical patent/IL213648A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
IL213648A 2003-05-02 2011-06-19 Optimized fc variants and uses thereof IL213648A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46760603P 2003-05-02 2003-05-02
US47783903P 2003-06-12 2003-06-12
US10/672,280 US20040132101A1 (en) 2002-09-27 2003-09-26 Optimized Fc variants and methods for their generation
PCT/US2004/009298 WO2004099249A2 (en) 2003-05-02 2004-03-26 Optimized fc variants and methods for their generation

Publications (2)

Publication Number Publication Date
IL213648A0 true IL213648A0 (en) 2011-07-31
IL213648A IL213648A (en) 2017-01-31

Family

ID=38312218

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213648A IL213648A (en) 2003-05-02 2011-06-19 Optimized fc variants and uses thereof

Country Status (5)

Country Link
JP (1) JP5226613B2 (en)
KR (1) KR100973564B1 (en)
CA (1) CA2766627C (en)
IL (1) IL213648A (en)
RU (1) RU2337107C2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
AU2011258425B2 (en) 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
CN103328632A (en) 2010-11-30 2013-09-25 中外制药株式会社 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
CA2839539C (en) 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
RU2739792C1 (en) 2011-11-30 2020-12-28 Чугаи Сейяку Кабусики Кайся Carrier containing a drug into a cell for forming an immune complex
JP6290209B2 (en) * 2012-08-07 2018-03-07 ロシュ グリクアート アーゲー A composition comprising two antibodies engineered to have reduced and increased effector function.
DK2889377T3 (en) * 2012-08-24 2020-03-30 Chugai Pharmaceutical Co Ltd Fc? RIIb-Specific Fc region variant
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
JP2016515524A (en) * 2013-03-15 2016-05-30 アッヴィ バイオテクノロジー リミテッド Anti-CD25 antibodies and their use
EP4039281A1 (en) * 2013-03-15 2022-08-10 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
CA2903587C (en) 2013-03-15 2021-09-28 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
WO2014163101A1 (en) 2013-04-02 2014-10-09 中外製薬株式会社 Fc region variant
RU2740714C2 (en) * 2013-08-01 2021-01-20 Файв Прайм Терапьютикс, Инк. Afucosylated fibroblast growth factor fgfr2iiib receptor
ES2900898T3 (en) * 2014-04-07 2022-03-18 Chugai Pharmaceutical Co Ltd Bispecific immunoactivating antibodies
KR20170017916A (en) 2014-05-13 2017-02-15 추가이 세이야쿠 가부시키가이샤 T cell-redirected antigen-binding molecule for cells having immunosuppression function
JP6675329B2 (en) * 2014-06-12 2020-04-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Methods for selecting antibodies with altered FcRn interactions
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CR20170326A (en) 2014-12-19 2017-08-22 Chugai Pharmaceutical Co Ltd ANTIMIOSTATINE ANTIBODIES, POLYPEPTIDES CONTAINING VARIANTS FC REGIONS, AND METHODS OF USE
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
JP6925278B2 (en) 2015-11-18 2021-08-25 中外製薬株式会社 Method of enhancing humoral immune response
WO2017086367A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR20230079499A (en) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
CN106872713A (en) * 2016-12-27 2017-06-20 许洋 A kind of immunomic mass spectrometry kit and preparation method of trace protein in situ detection
KR20200099807A (en) * 2019-02-15 2020-08-25 아주대학교산학협력단 Antibody Fragment With Constant Region of Antibody and Uses Thereof
CN112397159B (en) * 2019-08-19 2024-03-22 金色熊猫有限公司 Automatic entry method and device for clinical test report, electronic equipment and storage medium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141024B1 (en) * 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
EP2364996B1 (en) * 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation

Also Published As

Publication number Publication date
CA2766627C (en) 2019-12-03
JP2009209150A (en) 2009-09-17
RU2005137578A (en) 2007-06-10
IL213648A (en) 2017-01-31
RU2337107C2 (en) 2008-10-27
JP5226613B2 (en) 2013-07-03
KR20090059170A (en) 2009-06-10
CA2766627A1 (en) 2004-11-18
KR100973564B1 (en) 2010-08-03

Similar Documents

Publication Publication Date Title
IL265538B (en) Optimized fc variants and uses thereof
IL213648A0 (en) OPTIMIZED Fc VARIANTS AND USES THEREOF
HK1248731A1 (en) Immunoglobulin variants and uses thereof
EP1606314A4 (en) Fc REGION VARIANTS
EP1539941A4 (en) Adzymes and uses thereof
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
IL179497A0 (en) Carboranylporphyrins and uses thereof
HK1088837A1 (en) Clk-peptide and slk-peptide
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0428391D0 (en) Connection and connection part
IL172510A0 (en) Antibodies and uses thereof
EP1612225A4 (en) Modified acacia and use thereof
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
HK1086853A1 (en) Dispersion and use thereof
GB0318546D0 (en) Quinoxalinones and their use
HK1209049A1 (en) Survivin-derived peptides and use thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
EP1487547A4 (en) Physical interaction means and related uses thereof
AU2003228397A8 (en) Hausp-p53 interaction and uses thereof
AU2003216442A8 (en) Enkurin and uses thereof
EP1699809A4 (en) Amniotic-derived peptide and uses thereof
GB0312990D0 (en) Peptides and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed